[Inhibition of platelet aggregation (Update 2023)].
Thrombozytenaggregationshemmer (Update 2023).
Acute atherothrombosis
Diabetes mellitus
Platelets anti platelet drugs
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
22
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in patients with diabetes. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in patients with diabetes according to current scientific evidence. Akute atherothrombotische Komplikationen tragen, im Rahmen der beschleunigten Atherosklerose, zur kardiovaskulären Morbidität und Mortalität von Menschen mit Diabetes bei. Die Hemmung der Thrombozytenaggregation kann das Risiko für das Auftreten akuter atherothrombotischer Komplikationen reduzieren. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz von Thrombozytenaggregationshemmern dar.
Autres résumés
Type: Publisher
(ger)
Akute atherothrombotische Komplikationen tragen, im Rahmen der beschleunigten Atherosklerose, zur kardiovaskulären Morbidität und Mortalität von Menschen mit Diabetes bei. Die Hemmung der Thrombozytenaggregation kann das Risiko für das Auftreten akuter atherothrombotischer Komplikationen reduzieren. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz von Thrombozytenaggregationshemmern dar.
Identifiants
pubmed: 37101038
doi: 10.1007/s00508-023-02168-6
pii: 10.1007/s00508-023-02168-6
pmc: PMC10133352
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
161-163Informations de copyright
© 2023. The Author(s).
Références
The Task Force for diabetes, pre-diabetes, and cardiovascular diseases oft he ESC and the EASD. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;2020(41):255–323.
The antithrombotic trialists collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
doi: 10.1136/bmj.324.7329.71
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.
doi: 10.1001/jama.295.3.306
pubmed: 16418466
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–41.
doi: 10.1001/jama.2008.623
pubmed: 18997198
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
doi: 10.1136/bmj.a1840
pubmed: 18927173
pmcid: 2658865
The antithrombotic trialists collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.
doi: 10.1016/S0140-6736(09)60503-1
The ASCEND study collaborative group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;18(379):1529–39.
doi: 10.1056/NEJMoa1804988